Tandem Diabetes (TNDM) Tops Q4 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Tandem Diabetes Care Reports 2018 Financial Results and 2019 Financial Guidance
February 26, 2019 4:05 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2018 and financial guidance for the year ending December 31, 2019.
In comparing the fourth quarter of 2018 to the same period of 2017:
Pump shipments increased 133 percent to 16,168 pumps from 6,950 pumps Sales increased 89 percent to $76.2 million from $40.3 million Operating margin improved to 1 percent from negative 24 percentIn comparing the year ended December 31, 2018 to the same period of 2017:
... More